ReviewClinical reviews in allergy & immunology2013
Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema.
Review in Clinical reviews in allergy & immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Efficacy and safety ofPharmaceutical biology · 2023Pooled it
- Sequence variant affects GCSAML splicing, mast cell specific proteins, and risk of urticaria.Communications biology · 2023Pooled it
- Circulating vitamin D concentrations and the risk of urticaria: A bidirectional two-sample Mendelian randomization study.Asia Pacific journal of clinical nutrition · 2025Article
- Effect of benralizumab on inflammation in skin after intradermal allergen challenge in patients with moderate-to-severe atopic dermatitis.The journal of allergy and clinical immunology. Global · 2024Article
- Identification of key genes and molecular mechanisms of chronic urticaria based on bioinformatics.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Immunological signature of chronic spontaneous urticaria (Review).Experimental and therapeutic medicine · 2022Review
- Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.Clinical reviews in allergy & immunology · 2021Review
- Eosinophils in skin diseases.Seminars in immunopathology · 2021Review
- Management of Pediatric Chronic Spontaneous Urticaria: A Review of Current Evidence and Guidelines.Journal of asthma and allergy · 2021Review
- Review
- An adolescent girl with premature ovarian failure, Graves' disease, and chronic urticaria: a case report.Journal of medical case reports · 2020Article
- Significant predictive factors of the severity and outcomes of the first attack of acute angioedema in children.BMC pediatrics · 2019Article
- Emerging Therapies in Chronic Spontaneous Urticaria.Allergy, asthma & immunology research · 2019Review
- Causal Relationship Between Anti-TPO IgE and Chronic Urticaria byAllergy, asthma & immunology research · 2019Article
- Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.Drug design, development and therapy · 2019Article
- Article
- Autoimmune Theories of Chronic Spontaneous Urticaria.Frontiers in immunology · 2019Review
- Looking forward to new targeted treatments for chronic spontaneous urticaria.Clinical and translational allergy · 2017Review
- Leukotriene receptor antagonists for chronic urticaria: a systematic review.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2014Review
- Less travelled roads in clinical immunology and allergy: drug reactions and the environmental influence.Clinical reviews in allergy & immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urticaria and angioedema are common disorders. Chronic urticaria is defined as lasting longer than 6 weeks. Causes of chronic urticaria fall into the following categories: physical, allergic, hereditary, autoimmune, and idiopathic. Basophils and mast cells are the primary effector cells responsible for clinical symptoms and signs. These cells produce and secrete a variety of mediators including histamine, leukotrienes, prostaglandins, cytokines, chemokines, and other pro-inflammatory mediators. This leads to vasodilation, fluid exudation, increased vascular permeability, and accumulation of additional secondary inflammatory cells. Two mechanisms have been investigated as possibly contributing to the pathogenesis of chronic urticaria. One is the development of autoantibodies to FcεRI or IgE on mast cells and basophils. This appears to be responsible for 30-50 % of cases. The other is dysregulation of intracellular signaling pathways involving Syk, SHIP-1, or SHIP-2 in basophils and mast cells. The primary treatment for chronic urticaria is to treat the underlying pathology, if any can be identified. Otherwise, in idiopathic cases, H1 antihistamines, H2 antihistamines, antileukotrienes, and corticosteroids constitute the main pharmacologic treatment modalities. In severe and recalcitrant cases of chronic and autoimmune urticaria, immunosuppressive drugs have been used, most commonly cyclosporin. More recent experimental studies have also suggested that omalizumab, an anti-IgE therapy, may be of benefit. Currently, inhibitors of Syk are also being developed and tested in the laboratory and in animal models. As our understanding of the pathogenesis of idiopathic urticaria increases, development of additional drugs targeting these pathways may provide relief for the significant physical and psychological morbidity experienced by patients with this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.